Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis
about
Chemotherapy of second stage human African trypanosomiasis: comparison between the parenteral diamidine DB829 and its oral prodrug DB868 in vervet monkeysRepurposing of the Open Access Malaria Box for Kinetoplastid Diseases Identifies Novel Active Scaffolds against Trypanosomatids.Pharmacokinetic comparison to determine the mechanisms underlying the differential efficacies of cationic diamidines against first- and second-stage human African trypanosomiasis.The inward rectifier current inhibitor PA-6 terminates atrial fibrillation and does not cause ventricular arrhythmias in goat and dog models.In vitro and in vivo evaluation of 28DAP010, a novel diamidine for treatment of second-stage African sleeping sicknessBis-benzimidazole hits against Naegleria fowleri discovered with new high-throughput screens.Treatment options for second-stage gambiense human African trypanosomiasis.A new approach to chemotherapy: drug-induced differentiation kills African trypanosomes.Synthesis, antimicrobial, and antiproliferative activities of substituted phenylfuranylnicotinamidines.Independence from Kinetoplast DNA maintenance and expression is associated with multidrug resistance in Trypanosoma brucei in vitro.The animal trypanosomiases and their chemotherapy: a reviewIndole and Benzimidazole Bichalcophenes: Synthesis, DNA Binding and Antiparasitic Activity.
P2860
Q28543200-791EBB77-D32F-4959-AD24-125B89A15B2CQ30487641-B40771C3-21A0-40ED-AEE3-2BA5BA00E653Q33798222-4AC1336E-566C-47B0-AF84-D5B74FD92FDFQ33911538-C7CCCEDB-733E-4DB7-8029-BB3680B831D6Q34058294-515783FD-2D98-4AC8-BBBF-F24FFCC7E11AQ35169050-67CE92F8-1CC5-4935-A62F-CC7224646D2DQ36551049-01361B9F-FC26-4E43-8B89-135E673CF3F9Q36638375-8A6819A1-B91E-4C1B-A067-7189EAF14D2FQ36697144-630EF19E-2C9D-4B8E-920A-1AA1D1CAA6AAQ38848911-7260E292-6445-4C44-A938-BE6914D23E46Q38975883-DC3E735E-1826-4BE3-BBCF-01C96CCC0244Q46444190-08F3F9F2-BEC3-4505-9C55-C9CD1B9D5623
P2860
Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetics, Trypanosoma ...... human African trypanosomiasis
@en
Pharmacokinetics, Trypanosoma ...... human African trypanosomiasis.
@nl
type
label
Pharmacokinetics, Trypanosoma ...... human African trypanosomiasis
@en
Pharmacokinetics, Trypanosoma ...... human African trypanosomiasis.
@nl
prefLabel
Pharmacokinetics, Trypanosoma ...... human African trypanosomiasis
@en
Pharmacokinetics, Trypanosoma ...... human African trypanosomiasis.
@nl
P2093
P2860
P50
P921
P356
P1476
Pharmacokinetics, Trypanosoma ...... human African trypanosomiasis
@en
P2093
David W Boykin
Michael Zhuo Wang
P2860
P304
P356
10.1128/AAC.00398-13
P407
P577
2013-08-19T00:00:00Z